There are various factors that appear to predict the development of<unk>  symptoms. Genetically, there are currently multiple single nucleotide polymorphisms potentially associated with<unk> , as identified through the Genome Wide Association Studies. The reported polymorphisms are associated with a range of protein including voltage-gated sodium channels, Schwann cell function-related proteins, receptors for cell surface collagen, receptors involved in neuronal apoptosis, neuronal crest cell development, and an enzyme involved in pyruvate metabolism. Additionally, there are various diagnoses that may increase a patient's risk of developing<unk> : 1) A history with acquired or hereditary neuropathy from diabetes, renal disease, hypothyroidism, connective tissue disease, or vitamin deficiencies is a risk factor. 2) A diagnosis of current or previous infectious disease such as Human Immunodeficiency Virus, Poliomyelitis, and Hepatitis B or C may increase a patient's risk. 3) Exposure to medications linked to neurotoxicity, such as cyclosporine, vancomycin, and cimetidine, in the treatment of a previous diagnosis. There are also personal and treatment characteristics that may be potential risk factors: 1) Older age 2)<unk>  type 3) Cumulative dosage of<unk>  treatment 4) Smoking history 5) History of alcohol intake 6) Dietary history 7) Race 8) Gender 9) Inactive lifestyle. In particular, the cumulative dosage of<unk> utic agents is a well-recognized risk factor of<unk> .
Chemotherapy-induced peripheral neuropathy
Diabetic neuropathy
Tropical neuropathy
Progressive inflammatory neuropathy
Vasculitic neuropathy
Small fiber peripheral neuropathy
Alcoholic polyneuropathy
Chronic inflammatory demyelinating polyneuropathy